Key result
Using the TYRX antibacterial envelope during CIED procedures was estimated to yield a cost saving of £624 per patient as a primary preventative measure against infection.
Why the study?
Infection is a serious and expensive complication of CIED procedures, prompting an analysis to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure.
Does the TYRX antibacterial envelope reduce costs and infections in HFrEF patients undergoing ICD or CRT procedures?
Cohort (n=159)
No
Does the TYRX antibacterial envelope reduce costs and infections in HFrEF patients undergoing ICD or CRT procedures?
Answers are grounded in this paper and cite their sources.
The use of the TYRX antibacterial envelope during CIED procedures in HFrEF patients is estimated to be cost-saving for the NHS.
BACKGROUND AND AIMS: Infection is a serious and expensive complication of Cardiac Implantable Electronic Device (CIED) procedures. A retrospective based cost analysis was performed to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure against infection in a tertiary referral centre in South London, UK. METHODS: A retrospective cohort of heart failure patients with reduced ejection fraction undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) procedures were evaluated. Decision-analytic modelling was performed to determine economic savings of using the envelope during CIED procedure vs CIED procedure alone. RESULTS: Over a 12 month follow-up period following CIED procedure, the observed infection rate was 3.14% (n = 5/159). The average cost of a CIED infection inpatient admission was £41,820 and, further to economic analysis, the additional costs attributable to infection was calculated at £62,213.94. A cost saving of £624 per patient by using TYRX during CIED procedure as a primary preventative measure against infection was estimated. CONCLUSIONS: TYRX would be a cost-saving treatment option amongst heart failure patients undergoing ICD and CRT device procedures based on analysis in the local geographical area of South London. If upscaled to the UK population, we estimate potential cost savings for the National Health Service (NHS).
No takes yet. Share an insight, caveat, or question.
Burnhope et al. (2019) conducted a cohort in Heart failure with reduced ejection fraction (n=159). TYRX antibacterial envelope vs. CIED procedure alone was evaluated on Economic savings (£624 cost saving per patient). Using the TYRX antibacterial envelope during CIED procedures was estimated to yield a cost saving of £624 per patient as a primary preventative measure against infection.
Synapse has enriched 10 related papers. Consider them for comparative context: